Astrana Health (ASTH) to Release Quarterly Earnings on Thursday

Astrana Health (NASDAQ:ASTH) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Astrana Health to post earnings of $0.33 per share and revenue of $985.6860 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:30 PM ET.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.29 by $0.45. The business had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a net margin of 0.86% and a return on equity of 9.22%. Astrana Health’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 earnings per share. On average, analysts expect Astrana Health to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Astrana Health Price Performance

Shares of ASTH opened at $36.47 on Thursday. Astrana Health has a fifty-two week low of $18.08 and a fifty-two week high of $51.60. The firm’s 50-day simple moving average is $41.69 and its two-hundred day simple moving average is $32.10. The stock has a market cap of $2.03 billion, a PE ratio of 59.79 and a beta of 0.89. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.35 and a current ratio of 1.35.

Hedge Funds Weigh In On Astrana Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its holdings in shares of Astrana Health by 6.2% during the 4th quarter. State Street Corp now owns 1,675,516 shares of the company’s stock valued at $41,570,000 after acquiring an additional 98,064 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Astrana Health by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock valued at $25,513,000 after purchasing an additional 12,212 shares during the last quarter. Wellington Management Group LLP lifted its position in Astrana Health by 418.3% during the fourth quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock valued at $18,331,000 after purchasing an additional 596,293 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Astrana Health by 19.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 500,527 shares of the company’s stock valued at $14,190,000 after purchasing an additional 80,465 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Astrana Health by 231.0% in the third quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock worth $12,540,000 after purchasing an additional 308,665 shares during the last quarter. Institutional investors own 52.77% of the company’s stock.

Analysts Set New Price Targets

ASTH has been the topic of several recent research reports. Barclays upgraded Astrana Health from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $37.00 to $50.00 in a research note on Tuesday, May 26th. Needham & Company LLC boosted their target price on Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Robert W. Baird set a $45.00 target price on Astrana Health in a research note on Friday, May 8th. Truist Financial raised their price target on Astrana Health from $38.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Finally, TD Cowen lifted their price target on Astrana Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Astrana Health currently has an average rating of “Moderate Buy” and a consensus target price of $47.86.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.